Search bioRxiv⌕ Search

Biology subjects

Carrero, Z.

Publications and source records attributed to Carrero, Z..

2 recordsLinked to original sources

Counterfactual Diffusion Models for Mechanistic Explainability of Artificial Intelligence Models in Pathology

Deep learning can extract predictive and prognostic biomarkers from histopathology whole slide images. However, explainable artificial intelligence approaches widely used in digital pathology, such as attention heatmaps and class activation mapping, offer only limited interpretability regarding the features captured by classifiers. Here, we present MoPaDi (Morphing histoPathology Diffusion), a framework for generating counterfactual explanations for histopathology images that reveal which morphological or style features drive classifier predictions. MoPaDi combines diffusion autoencoders with task-specific multiple instance learning classifiers to manipulate images and flip predictions by modifying relevant features. We evaluated the framework on multiple datasets spanning colorectal, breast, liver, and lung cancers, including tissue type, cancer subtype, and biomarker (microsatellite instability) classification tasks. We assessed counterfactual explanations through quantitative analyses, pathologists evaluations, and independent foundation model-based classifiers. We found that MoPaDi was able to generate realistic counterfactual histopathology images, enabling pathologists to identify morphological features associated with the change in model predictions. Unlike conventional reviews of highly attended regions typical in digital pathology, MoPaDi explanations enabled pathologists to directly identify morphological features driving the classifiers predictions from a limited number of top-contributing tiles. Consistent with the literature, our biomarker classifier associated high microsatellite instability with mucinous differentiation, glandular patterns, and lymphocytic infiltration. Furthermore, MoPaDi revealed that changes in classifier predictions were mainly driven by morphological alterations rather than staining differences. Overall, MoPaDi is a practical framework for counterfactual explanations in computational pathology that reveals model-specific drivers of classification and increases trust in deep learning models.

bioinformatics↗

Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 Fusions

Linking clinical multi-omics analyses with mechanistic studies provides opportunities to explore the pathogenesis of rare cancers. We leveraged two precision oncology programs to investigate rhabdomyosarcoma with FUS/EWSR1-TFCP2 fusions, an orphan malignancy without effective systemic therapies. All tumors exhibited outlier expression of the ALK receptor tyrosine kinase, which was partly accompanied by intragenic deletions and aberrant splicing, resulting in truncated ALK variants that were oncogenic and sensitive to ALK inhibitors. Additional recurrent alterations included CKDN2A/MTAP co-deletions, providing a rationale for therapies targeting CDK4/6 and PRMT5. Functional studies showed that FUS-TFCP2 blocks myogenic differentiation and induces transcription of ALK and a truncated form of TERT through binding outside their regular promoters. Furthermore, FUS-TFCP2 inhibited DNA double-strand break repair. Consistent with this, and unlike other fusion-driven sarcomas, TFCP2-rearranged tumors exhibited marked genomic instability and signs of defective homologous recombination. DNA methylation profiling indicated a close relationship with undifferentiated sarcomas rather than rhabdomyosarcoma. Finally, we identified patients in whom overt disease was preceded by benign lesions carrying TFCP2 fusions, providing insight into stepwise sarcomagenesis and suggesting new approaches to early detection and interception. SIGNIFICANCEMost rare cancers are poorly understood, and pathogenesis-directed therapies are often lacking, resulting in poor patient outcomes. This study illustrates the potential of linking precision oncology programs with preclinical research to gain insight into the classification, pathogenesis, and therapeutic vulnerabilities of rare cancers that could improve the clinical management of such diseases.

cancer biology↗